Pembrolizumab is still the only IT used in Serbia for NSCLC treatment, as the first-line single therapy for patients with high (≥50%) PD-L1 expression in the IV stage of the disease, with negative driver mutations [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.